Takeda Starts Japanese Fiscal Year With Global Reorganization
This article was originally published in PharmAsia News
Executive Summary
Takeda unveiled an ambitious plan March 31, the day before Japan's new fiscal year, to reorganize its corporate structure in a quest to become a "global pharmaceutical company with highly integrated global operations.
You may also be interested in...
Takeda Halts Development Of Diabetes Agent TAK-379
Takeda announced April 21 it would discontinue clinical development of diabetes agent TAK-379 because it did not meet internal criteria to support further development. An insulin sensitizer, TAK-379 was in Phase II trials in the U.S. and Europe and in Phase I in Japan
Takeda Halts Development Of Diabetes Agent TAK-379
Takeda announced April 21 it would discontinue clinical development of diabetes agent TAK-379 because it did not meet internal criteria to support further development. An insulin sensitizer, TAK-379 was in Phase II trials in the U.S. and Europe and in Phase I in Japan
Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies